For decades, doctors believed that restoring blood flow was the final battle in saving the brain after a stroke. Yet for countless patients, the real damage begins after treatment when bleeding, swelling, and slow recovery quietly take over. Now, scientists may have uncovered why?
Researchers from the Chinese Academy of Sciences (CAS) have identified a protein that appears to sabotage the brain’s own recovery process following an ischaemic stroke, revealing a potential breakthrough for future life-saving therapies.
Ischaemic stroke remains one of the world’s deadliest and most disabling conditions. While modern medicine can reopen blocked blood vessels, many patients continue to deteriorate due to secondary brain injury.
Until now, the biological trigger behind this delayed destruction remained largely unexplained.
According to a study published in the European Heart Journal, scientists at the Shenzhen Institutes of Advanced Technology (SIAT) discovered that a protein called DKK2 surges in the brain after a stroke.
Released by neurons under extreme stress, the protein was expected to protect fragile brain tissue. Instead, it does the opposite.
The research shows that DKK2 shuts down a critical survival pathway that keeps brain cells alive and blood vessels intact.
As this protective system collapses, the blood–brain barrier weakens, allowing hemorrhages to occur and causing the area of dead brain tissue to spread further.
In laboratory experiments, mice with suppressed DKK2 activity showed significantly smaller brain injuries and stronger neurological recovery.
However, when DKK2 levels were artificially increased, the damage intensified confirming the protein’s destructive role.
The twist became even more striking when researchers turned to human patients. Blood samples from stroke survivors revealed that those with higher DKK2 levels suffered more severe brain injury and faced poorer recovery outcomes even three months later.
By exposing this hidden molecular trigger, scientists believe DKK2 could become a critical target for future stroke treatments.
Regulating the protein may help protect the brain, limit secondary damage, and offer hope to patients who miss the narrow time window for conventional therapies.
Sometimes, the greatest threat isn’t the stroke itself but the silent biological reaction that follows.
